Loading clinical trials...
Loading clinical trials...
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.
Conditions
Interventions
CV-MG01
Placebo
Locations
1
Belgium
University Hospital, Antwerp
Edegem, Antwerp, Belgium
Start Date
July 1, 2018
Primary Completion Date
October 1, 2019
Completion Date
December 31, 2019
Last Updated
May 30, 2018
NCT06485232
NCT00683969
Lead Sponsor
CuraVac
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions